Advanced search
Publication Cover
Journal of Chemotherapy Volume 35, 2023 - Issue 2
Submit an article Journal homepage
378
Views
0
CrossRef citations to date
0
Altmetric
Anticancer Original Research Papers

Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study

Tuğba Başoğlua Medical Oncology, Marmara University School of Medicine, İstanbul, TurkeyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2059-5502View further author information
ORCID Icon,
Abdullah Sakinb Medical Oncology, Van Yuzuncu Yil University Faculty of Medicine, Van, TurkeyView further author information
,
Cihan Erolc Medical Oncology, Ankara Yildirim Beyazit Universtiy, Ankara, TurkeyView further author information
,
Ercan Özdend Medical Oncology, Kocaeli University Faculty of Medicine, Kocaeli, TurkeyView further author information
,
Devrim Çabukd Medical Oncology, Kocaeli University Faculty of Medicine, Kocaeli, TurkeyView further author information
,
Ebru Çılbıre Medical Oncology, Dışkapı Training and Research Hospital, Ankara, TurkeyView further author information
,
Deniz Tataroğlu Özyükselerf Medical Oncology, Kartal Dr.LütfiKırdar Training and Research Hospital, İstanbul, TurkeyORCID Iconhttps://orcid.org/0000-0002-0254-1084View further author information
ORCID Icon,
Murat Ayhanf Medical Oncology, Kartal Dr.LütfiKırdar Training and Research Hospital, İstanbul, TurkeyView further author information
,
Mehmet Ali Şendurc Medical Oncology, Ankara Yildirim Beyazit Universtiy, Ankara, TurkeyView further author information
,
Mutlu Dogang Medical Oncology, Ankara Dr.Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0001-9359-3770View further author information
ORCID Icon,
Berna Öksüzoğlug Medical Oncology, Ankara Dr.Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, TurkeyView further author information
,
Melek Karakurt Eryılmazh Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, TurkeyView further author information
,
Özlem Eri Medical Oncology, Acıbadem Mehmet Ali Aydınlar University School of Medicine, İstanbul, TurkeyView further author information
,
Elif Şenocak Taşçıi Medical Oncology, Acıbadem Mehmet Ali Aydınlar University School of Medicine, İstanbul, TurkeyView further author information
,
Neslihan Özyurtj Medical Oncology, Giresun Education and Research Hospital, Giresun, TurkeyView further author information
,
Özgecan Dülgark Medical Oncology, İstanbul Medeniyet University Göztepe Training and Research Hospital, İstanbul, TurkeyORCID Iconhttps://orcid.org/0000-0002-0678-4024View further author information
ORCID Icon,
Miraç Özenl Medical Oncology, Sakarya University Faculty of Medicine, Sakarya, TurkeyView further author information
,
İlhan Hacıbekiroğlul Medical Oncology, Sakarya University Faculty of Medicine, Sakarya, TurkeyView further author information
,
İrem Önerm Medical Oncology, Konya City Hospital, Konya, TurkeyView further author information
,
Esma Türkmen Bekmezn Medical Oncology, Derince Research and Training Hospital, Kocaeli, TurkeyView further author information
,
Hasan Çağrı Yıldırımo Medical Oncology, Hacettepe University School of Medicine, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0003-3060-377XView further author information
ORCID Icon,
Şuayib Yalçıno Medical Oncology, Hacettepe University School of Medicine, Ankara, TurkeyView further author information
,
Semra Paydaşp Medical Oncology, Cukurova University School of Medicine, Adana, TurkeyORCID Iconhttps://orcid.org/0000-0003-4642-3693View further author information
ORCID Icon,
Emre Yekedüzq Medical Oncology, Ankara University School of Medicine, Ankara, TurkeyView further author information
,
Asude Aksoyr Medical Oncology, Fırat University Faculty of Medicine, Elazığ, TurkeyView further author information
,
Melike Özçeliks Medical Oncology, Umraniye Training and Research Hospital, İstanbul, TurkeyView further author information
,
Abdilkerim Oymans Medical Oncology, Umraniye Training and Research Hospital, İstanbul, TurkeyView further author information
,
Elvina Almuradovat Medical Oncology, Ege University School of Medicine, İzmir, TurkeyView further author information
,
Bülent Karabulutt Medical Oncology, Ege University School of Medicine, İzmir, TurkeyView further author information
,
Nazan Demiru Medical Oncology, Eskişehir Osmangazi University School of Medicine, Eskişehir, TurkeyORCID Iconhttps://orcid.org/0009-0000-2988-4450View further author information
ORCID Icon,
Murat Dinçeru Medical Oncology, Eskişehir Osmangazi University School of Medicine, Eskişehir, TurkeyView further author information
,
Nuriye Özdemirv Medical Oncology, Gazi University School of Medicine, Ankara, TurkeyView further author information
,
Dilek Erdemw Medical Oncology, VM Medical Park Samsun Hospital, Samsun, TurkeyView further author information
,
Naziye Akx Medical Oncology, İstanbul University, İstanbul, TurkeyORCID Iconhttps://orcid.org/0000-0001-5790-7066View further author information
ORCID Icon,
Ali İnaly Medical Oncology, Mersin City Hospital, Mersin, TurkeyView further author information
,
Derya Kıvrak Salimz Medical Oncology, Antalya Training and Research Hospital, Antalya, TurkeyView further author information
,
Gülhan İpek Denizaa Medical Oncology, Sisli Hamidiye Etfal Training and Research Hospital, İstanbul, TurkeyView further author information
,
Teoman Şakalarab Medical Oncology, Necip Fazıl City Hospital, Kahramanmaraş, TurkeyView further author information
,
Ahmet Gülmezac Medical Oncology, İnönü University, Elazığ, TurkeyView further author information
,
Turgut Kaçanad Medical Oncology, Bursa High Specialized Education and Research Hospital, Bursa, TurkeyView further author information
,
Özlem Özdemirae Medical Oncology, İzmir Bozyaka Research and Training Hospital, İzmir, TurkeyView further author information
,
Özkan Alanaf Medical Oncology, Tekirdağ State Hospital, Tekirdağ, TurkeyORCID Iconhttps://orcid.org/0000-0002-6635-2012View further author information
ORCID Icon,
Çağlar Ünalag Medical Oncology, Florance Nightingale Hospital, İstanbul, TurkeyView further author information
,
Yusuf Karakaşah Medical Oncology, Bodrum Acıbadem Hospital, Muğla, TurkeyView further author information
,
Serdar Turhalai Medical Oncology, Anadolu SağlıkMerkezi Anadolu Health Center, İstanbul, TurkeyView further author information
&
Perran Fulden Yumuka Medical Oncology, Marmara University School of Medicine, İstanbul, TurkeyORCID Iconhttps://orcid.org/0000-0001-8650-299XView further author information
ORCID Icon show all
Pages 142-149 | Received 17 Nov 2021, Accepted 28 Apr 2022, Published online: 17 May 2022

References

  • Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209–249.
  • Inghelmann R, Grande E, Francisci S, et al. Regional estimates of stomach cancer burden in Italy. Tumori. 2007;93(4):367–373.
  • Wang ZL, Wang C, Liu W, et al. Emerging roles of the long non-coding RNA 01296/microRNA-143-3p/MSI2 axis in development of thyroid cancer. Biosci Rep. 2019;39(11):BSR20182376. doi:10.1042/BSR20182376.
  • De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncol. 2014;15(1):23–34.
  • Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
  • Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–1721.
  • Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–1957.
  • Chae S, Lee A, Lee J-H. The effectiveness of the new (7th) UICC N classification in the prognosis evaluation of gastric cancer patients: a comparative study between the 5th/6th and 7th UICC N classification. Gastric Cancer. 2011;14(2):166–171.
  • Langer R, Becker K. Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy. Virchows Arch. 2018;472(2):175–186.
  • Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med. 1995;333(1):32–41.
  • Al-Batran S-E, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17(12):1697–1708.
  • Li ZY, Koh CE, Bu ZD, et al. Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer. J Surg Oncol. 2012;105(8):793–799.
  • Ajani JA, Moiseyenko VM, Tjulandin S, V-325 Study Group, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 study group. J Clin Oncol. 2007;25(22):3205–3209.
  • Enzinger PC, Burtness BA, Niedzwiecki D, et al. CALGB 80403 (alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. J Clin Oncol. 2016;34(23):2736–2742.
  • Sun Z, Zhu R-J, Yang G-F, et al. Neoadjuvant chemotherapy with FOLFOX4 regimen to treat advanced gastric cancer improves survival without increasing adverse events: a retrospective cohort study from a Chinese center. Sci World J. 2014;2014:1–10.
  • Al-Batran S-E, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol. 2004;22(4):658–663.
  • Luo H-Y, Xu R-H, Zhang L, et al. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer. Chemotherapy. 2008;54(3):228–235.
  • De Vita F, Orditura M, Matano E, et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer. 2005;92(9):1644–1649.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.